KYMR Stock Analysis: Kymera Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 11.246m USD | 12M Return: 123.1% | US5015751044 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 109M
Qual. Beats: 0
Rev. Trend: -10.2%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 6.2 years of data, until 10/2026
Typical move per month (median of past years, trend removed). Green = up, red = down. Full color = reliable and tradable: trust ≥40 and move ≥2.5%; pale = not reliable or too small. ★ = strong: trust ≥60 and a move that is large for this stock's normal monthly swing, same rule as the Seasonal Tailwind / Headwind signal. Small number = trust score (0 = chance).
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing small molecule drugs that selectively degrade disease-causing proteins using the bodys natural protein degradation system, an approach known as targeted protein degradation. The company is headquartered in Watertown, Massachusetts, was incorporated in 2015, and trades on NASDAQ under the ticker KYMR.
The pipeline is built around several oral degrader programs. KT-621, an oral STAT6 degrader, is in Phase 2b trials for atopic dermatitis, asthma, COPD, and related conditions. KT-579, an oral IRF5 degrader, is in Phase 1 development for autoimmune diseases such as lupus, rheumatoid arthritis, and inflammatory bowel disease. The IRAK4 program (KT-485/SAR447971) is in Phase II for immunology-inflammation indications including hidradenitis suppurativa and atopic dermatitis, and is partnered with Sanofi S.A. outside the oncology and immuno-oncology fields. A separate CDK2 program targets oncology indications such as breast cancer and other solid tumors.
As a clinical-stage biotech without approved products, Kymeras business model relies on advancing candidates through trials and monetizing programs through partnerships, as illustrated by the Sanofi alliance. Its placement in the biotechnology sub-industry reflects a focus on platform-based drug discovery rather than commercial product sales, with the targeted protein degradation modality representing a relatively new class of therapeutics distinct from traditional small molecule inhibitors.
- KT-621 Phase 2b atopic dermatitis data readout approaches
- Sanofi IRAK4 partnership milestones validate pipeline and extend cash runway
- Rising R&D spending pressures cash position and operating margins
| Net Income: -349.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.16 > 0.02 and ΔFCF/TA 4.54 > 1.0 |
| NWC/Revenue: 889.1% < 20% (prev 1.04k%; Δ -155.2% < -1%) |
| CFO/TA -0.16 > 3% & CFO -287.6m > Net Income -349.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (100.1m) vs 12m ago 14.66% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 7.13% > 50% (prev 3.97%; Δ 3.16% > 0%) |
| Interest Coverage Ratio: -1.28k > 6 (EBIT TTM -349.4m / Interest Expense TTM 273k) |
| A: 0.51 (Total Current Assets 998.6m - Total Current Liabilities 89.7m) / Total Assets 1.77b |
| B: -0.75 (Retained Earnings -1.33b / Total Assets 1.77b) |
| C: -0.24 (EBIT TTM -349.4m / Avg Total Assets 1.43b) |
| D: 10.57 (Book Value of Equity 1.61b / Total Liabilities 152.7m) |
| Altman-Z'' = 10.39 = AAA |
As of November 11, 2026, the stock is trading at USD 136.64 with a total of 995,052 shares traded. Over the past week, the price has changed by +7.51%, over one month by +21.91%, over three months by +25.84% and over the past year by +123.05%.
Current recommended Stop Loss: 127.80 (which is 6.5% or 1.3 ATR below the current price).
Kymera Therapeutics has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy KYMR.
- StrongBuy: 17
- Buy: 5
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 144.6 | 5.8% |
P/S = 110.0012
P/B = 6.9655
Revenue TTM = 102.2m USD
EBIT TTM = -349.4m USD
EBITDA TTM = -341.3m USD
Long Term Debt = 63.0m USD (estimated: total debt 76.6m - short term 13.6m)
Short Term Debt = 13.6m USD (from shortTermDebt, last quarter)
Debt = 76.6m USD (from shortLongTermDebtTotal, last quarter) (leases 76.6m already included)
Net Debt = -894.6m USD (calculated: Debt 76.6m - CCE 971.2m)
Enterprise Value = 10.4b USD (11.2b + Debt 76.6m - CCE 971.2m)
Interest Coverage Ratio = -1.28k (Ebit TTM -349.4m / Interest Expense TTM 273k)
EV/FCF = -35.83x (Enterprise Value 10.4b / FCF TTM -288.9m)
FCF Yield = -2.79% (FCF TTM -288.9m / Enterprise Value 10.4b)
FCF Margin = -282.6% (FCF TTM -288.9m / Revenue TTM 102.2m)
Net Margin = -341.9% (Net Income TTM -349.5m / Revenue TTM 102.2m)
Gross Margin = unknown ((Revenue TTM 102.2m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 5.86 (Enterprise Value 10.4b / Total Assets 1.77b)
Interest Expense / Debt = 0.36% (Interest Expense 273k / Debt 76.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -276.0m (EBIT -349.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.13 (Total Current Assets 998.6m / Total Current Liabilities 89.7m)
Debt / Equity = 0.05 (Debt 76.6m / totalStockholderEquity, last quarter 1.61b)
Debt / EBITDA = 2.62 (negative EBITDA) (Net Debt -894.6m / EBITDA -341.3m)
Debt / FCF = 3.10 (negative FCF - burning cash) (Net Debt -894.6m / FCF TTM -288.9m)
Total Stockholder Equity = 1.56b (last 4 quarters mean from totalStockholderEquity)
RoA = -24.36% (Net Income -349.5m / Total Assets 1.77b)
RoE = -22.39% (Net Income TTM -349.5m / Total Stockholder Equity 1.56b)
RoCE = -21.52% (EBIT -349.4m / Capital Employed (Equity 1.56b + L.T.Debt 63.0m))
RoIC = -16.37% (negative operating profit) (NOPAT -276.0m / Invested Capital 1.69b)
WACC = 9.30% (E(11.2b)/V(11.3b) * Re(9.36%) + D(76.6m)/V(11.3b) * Rd(0.36%) * (1-Tc(0.21)))
Discount Rate = 9.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.37 | Cagr: 15.02%
[DCF] Fair Price = unknown (Cash Flow -288.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.47 | # QB: 0
Revenue Correlation: -10.22 | Revenue CAGR: -3.99% | SUE: -0.15 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-1.35 | Chg30d=+0.86% | Revisions=+0% | Analysts=7
EPS current Year (2026-12-31): EPS=-3.93 | Chg30d=-2.29% | Revisions=-46% | GrowthEPS=-6.4% | GrowthRev=+153.5%
EPS next Year (2027-12-31): EPS=-5.12 | Chg30d=-0.37% | Revisions=-13% | GrowthEPS=-30.3% | GrowthRev=-57.7%
[Analyst] Revisions Ratio: -30% (up=8, down=16)